Skip to main content

Sanofi is close to a $11.4 billion deal for Bioverativ: source

French drugmaker Sanofi is close to acquiring biotechnology company Bioverativ for $105 a share.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.